Abstract

BackgroundTreatment with a daily fixed dose combination of ledipasvir/sofosbuvir (LDV/SOF) in tablet form, with and without ribavirin (RBV), has exhibited promising results for the treatment of patients with hepatitis C...

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call